Cargando…

ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection

BACKGROUND & AIM: Whether inosine triphosphatase (ITPA) gene polymorphisms predict anemia during interferon-free therapy in chronic hepatitis C virus (HCV)-infected patients is unknown. We examined the relationship between two ITPA polymorphisms, anemia, and sustained virological response 12 wee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Asselah, Tarik, Zeuzem, Stefan, Soriano, Vicente, Bronowicki, Jean-Pierre, Lohse, Ansgar W., Müllhaupt, Beat, Schuchmann, Marcus, Bourlière, Marc, Buti, Maria, Roberts, Stuart K., Gane, Edward J., Stern, Jerry O., Voss, Florian, Baum, Patrick, Gallivan, John-Paul, Böcher, Wulf O., Mensa, Federico J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674133/ https://www.ncbi.nlm.nih.gov/pubmed/26650626 http://dx.doi.org/10.1371/journal.pone.0144004

Ejemplares similares

HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection
por: Sarrazin, Christoph, et al.
Publicado: (2016)

Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir
por: Berger, Kristi L., et al.
Publicado: (2016)

SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients
por: Dieterich, Douglas, et al.
Publicado: (2014)

HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment
por: Sarrazin, Christoph, et al.
Publicado: (2016)

Faldaprevir for the Treatment of Hepatitis C
por: Kanda, Tatsuo, et al.
Publicado: (2015)

Roles of ITPA and IL28B Genotypes in Chronic Hepatitis C Patients Treated with Peginterferon Plus Ribavirin
por: Miyamura, Tatsuo, et al.
Publicado: (2012)

Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis
por: Pineda-Tenor, Daniel, et al.
Publicado: (2015)

The ITPA and C20orf194 Polymorphisms and Hematological Changes During Treatment With Pegylated-Interferon Plus Ribavirin in Patients With Chronic Hepatitis C
por: Pouryasin, Mohammad, et al.
Publicado: (2016)

A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin
por: Asselah, Tarik, et al.
Publicado: (2016)

IFI35, mir-99a and HCV Genotype to Predict Sustained Virological Response to Pegylated-Interferon Plus Ribavirin in Chronic Hepatitis C
por: Estrabaud, Emilie, et al.
Publicado: (2015)

Associations of ITPA gene polymorphisms with outcomes among chronic hepatitis C patients treated with Peg-interferon/ribavirin: A 5-year follow-up study
por: Liu, Zhenhua, et al.
Publicado: (2023)

The rs1127354 Polymorphism in ITPA Is Associated with Susceptibility to Infertility
por: Mollaahmadi, Fahimeh, et al.
Publicado: (2018)

ITPA Related Developmental Encephalopathy: Key Role of Neuroimaging
por: Çavuşoğlu, Dilek, et al.
Publicado: (2022)

Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response
por: Asselah, Tarik, et al.
Publicado: (2017)

Severe thrombocytopenia in a patient with inosine triphosphatase (ITPA)–CC genotype caused by pegylated interferon (IFN)-α-2a with ribavirin therapy: a case report
por: Jiang, Weimin, et al.
Publicado: (2014)

Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin
por: Asselah, Tarik, et al.
Publicado: (2010)

ITPA Polymorphisms and the Incidence of Toxicities in Children with Acute Lymphoblastic Leukemia
por: Svasdisant, Patpetra, et al.
Publicado: (2023)

An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)
por: Asselah, Tarik, et al.
Publicado: (2016)

A disease spectrum for ITPA variation: advances in biochemical and clinical research
por: Burgis, Nicholas E.
Publicado: (2016)

Identification of ITPA on chromosome 20 as a susceptibility gene for young-onset tuberculosis
por: Nakauchi, Ayaka, et al.
Publicado: (2016)

Neural stem cell–specific ITPA deficiency causes neural depolarization and epilepsy
por: Koga, Yuichiro, et al.
Publicado: (2020)

Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents
por: Shiffman, Mitchell L, et al.
Publicado: (2016)

Characterization of the structure and expression of mouse Itpa gene and its related sequences in the mouse genome
por: Behmanesh, M., et al.
Publicado: (2015)

Measuring deaminated nucleotide surveillance enzyme ITPA activity with an ATP-releasing nucleotide chimera
por: Ji, Debin, et al.
Publicado: (2017)

Influence of Ribavirin Serum Levels on Outcome of Antiviral Treatment and Anemia in Hepatitis C Virus Infection
por: Kuntzen, Thomas, et al.
Publicado: (2016)

Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme
por: Hézode, Christophe, et al.
Publicado: (2017)

ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection
por: Maan, Raoel, et al.
Publicado: (2015)

Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease
por: Bernstein, David E., et al.
Publicado: (2018)

Limited Utility of ITPA Deficiency to Predict Early Anemia in HCV Patients with Advanced Fibrosis Receiving Telaprevir
por: Aghemo, Alessio, et al.
Publicado: (2014)

Prevalence of TPMT and ITPA gene polymorphisms and effect on mercaptopurine dosage in Chilean children with acute lymphoblastic leukemia
por: Farfan, Mauricio J, et al.
Publicado: (2014)

A Simple Method for TPMT and ITPA Genotyping Using Multiplex HRMA for Patients Treated with Thiopurine Drugs
por: Skrzypczak-Zielinska, Marzena, et al.
Publicado: (2016)

The relationship between ITPA rs1127354 polymorphisms and efficacy of antiviral treatment in Northeast Chinese CHC patients
por: Liu, Zhenhua, et al.
Publicado: (2017)

Ribavirin
Publicado: (2016)

Ribavirin
por: Hall, Caroline Breese
Publicado: (1985)

“Six-and-twelve” score for outcome prediction of hepatocellular carcinoma following transarterial chemoembolization. In-depth analysis from a multicenter French cohort
por: Adhoute, Xavier, et al.
Publicado: (2020)

Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response
por: Chak, Eric, et al.
Publicado: (2010)

Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study
por: About, Frédégonde, et al.
Publicado: (2015)

Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older
por: Foster, Graham R., et al.
Publicado: (2019)

Pharmacogenetic Analysis of Pediatric Patients with Acute Lymphoblastic Leukemia: A Possible Association between Survival Rate and ITPA Polymorphism
por: Kim, Hyery, et al.
Publicado: (2012)

Association of ITPA Genotype with Event-Free Survival and Relapse Rates in Children with Acute Lymphoblastic Leukemia Undergoing Maintenance Therapy
por: Smid, Alenka, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_35dc2gf4bqp8strsd8jg05k1d9